Amgen Inc.

Leland Stanford Junior University

Amgen Research (Munich) Gmbh

Darren L Bates

Zhulun Wang

Ian Nevin Foltz

Neeraj Jagdish Agrawal

Xiaoshan Min

Donghui Shi

David J Lloyd

Murielle M Veniant-Ellison

Junming Yie

Christopher Murawsky

K Christopher Garcia

Jinghong Wang

Renee Komorowski

Brandon C P Clavette

Shu-yin Ho

Ignacio Moraga

Glenn N Sivits, Jr

Tobias Raum

Gunasekaran Kannan

Mark Leo Michaels

Christoph Dahlhoff

Pavel V Bondarenko

Irwin Chen

Marissa Mock

Christopher K Garcia

Olivier Nolan-Stevaux

Khaled M K Z Ali

Shunsuke Takenaka

Agnieszka Kielczewska

Claudia Bluemel

Nathan William Pierce

Todd Hager

Aiko Umeda

Lisa Winkel

Jonas Karl-Josef Honer

Wentao Chen

Ian Foltz

Khaled MKZ Ali

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.

Anti-CCR8 antibodies and uses thereof

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.

Method of producing Th9 T-cells

Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.

Interleukin-21 mutein/ anti-PD-1 antibody conjugates

Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Growing community of inventors

Oak Park, CA, United States of America

Darren L Bates